Akebia Therapeutics AKBA
NASDAQ AKBA
$0.59 -0.03 (-5.31%)
At close: Oct 21, 2026 · 4:00 PM EDT

Akebia Therapeutics (AKBA) Short-Term Debt repayments (2019)

Updated

Akebia Therapeutics (AKBA) recorded Short-Term Debt repayments of $32 million in FY2023, down 3.0% from $33 million in FY2022.

Analysis

Akebia Therapeutics (AKBA) Short-Term Debt repayments (2019) Analysis & Trends

  • Annual Short-Term Debt repayments has a four-year compound annual growth rate of 20.9% (FY2019 to FY2023).
  • The FY2023 figure is the lowest annual Short-Term Debt repayments since FY2019.
  • Per Business Quant data, AKBA's Short-Term Debt repayments was $33 million in FY2022 and $15 million in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ST Debt Repayment (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn -
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 6.45 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn -
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 Akebia Therapeutics 157.80 Mn -511.68 Mn 38.70 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 15.00 Mn
API Access

Akebia Therapeutics Short-Term Debt repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt-repayments&ticker=AKBA&period=max&api_key=YOUR_API_KEY